Severity and morphology of cirAEs and eosinophil count
| Dupilumab (N=53) | Control 1 (N=106) | P value | |
| Severity of the first cirAE | |||
| 1 | 13 (24.5%) | 52 (49.1%) | 0.012 |
| 2 | 32 (60.4%) | 43 (40.6%) | |
| 3 | 8 (15.1%) | 11 (10.4%) | |
| Severity of the dupilumab-treated cirAE | |||
| 1 | 1 (1.9%) | N/A | |
| 2 | 42 (79.2%) | N/A | |
| 3 | 10 (18.9%) | N/A | |
| Morphology of the first cirAE | |||
| Eczematous dermatitis | 15 (28.3%) | 7 (6.6%) | <0.001 |
| Bullous pemphigoid | 10 (18.9%) | 3 (2.8%) | |
| Maculopapular eruption | 8 (15.1%) | 27 (25.5%) | |
| Lichenoid dermatitis | 5 (9.4%) | 7 (6.6%) | |
| Lichenoid dermatitis, eczematous dermatitis | 1 (1.9%) | 0 (0%) | |
| Lichenoid dermatitis, maculopapular eruption | 1 (1.9%) | 0 (0%) | |
| Radiation induced morphea ICB exacerbated | 1 (1.9%) | 0 (0%) | |
| Pruritus | 4 (7.5%) | 16 (15.1%) | |
| Psoriasiform eruption | 0 (0%) | 6 (5.7%) | |
| Vitiligo | 0 (0%) | 7 (6.6%) | |
| Rash, NOS | 8 (15.1%) | 33 (31.1%) | |
| Morphology of the dupilumab-treated cirAE | |||
| Eczematous dermatitis | 22 (41.5%) | N/A | |
| Bullous pemphigoid | 14 (26.4%) | N/A | |
| Lichenoid dermatitis | 7 (13.2%) | N/A | |
| Morbilliform drug eruption | 5 (9.4%) | N/A | |
| Lichenoid dermatitis, bullous pemphigoid | 1 (1.9%) | N/A | |
| Lichenoid dermatitis, eczematous dermatitis | 1 (1.9%) | N/A | |
| Lichenoid dermatitis, morbilliform drug eruption | 1 (1.9%) | N/A | |
| Radiation-induced morphea ICB exacerbated | 1 (1.9%) | N/A | |
| Sclerodermoid reaction with morphea-profunda | 1 (1.9%) | N/A | |
| ICB to the first cirAE, days | |||
| Median (Q1, Q3) | 63 (15, 198) | 54.5 (21, 155) | 0.395 |
| ICB to the dupilumab-treated cirAE, days | |||
| Median (Q1, Q3) | 146 (21, 414) | N/A | |
| ICB to the dupilumab initiation, days | |||
| Median (Q1, Q3) | 352 (184, 585) | N/A | |
| Dupilumab duration, days | |||
| Median (Q1, Q3) | 230 (124, 418) | N/A | |
| Absolute eosinophil count before dupilumab | |||
| Median (Q1, Q3) | 0.39 (0.18, 0.76) | N/A | |
| Absolute eosinophil count after dupilumab | |||
| Median (Q1, Q3) | 0.16 (0.07, 0.26) | N/A | |
| CBC before dupilumab, days | |||
| Median (Q1, Q3) | 26 (18.5, 61) | N/A | |
| CBC after dupilumab, days | |||
| Median (Q1, Q3) | 140 (72.5, 219) | N/A |
CBC, complete blood count; CirAE, cutaneous immune-related adverse event; ICB, immune checkpoint blockade; N/A, not available; NOS, not otherwise specified; Q1, the first quartile; Q3, the third quartile.